Shield Therapeutics plc
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a STX.L research report →
Companywww.shieldtherapeutics.com
Shield Therapeutics plc, a specialty pharmaceutical company, engages in the development and commercialization of clinical stage pharmaceuticals to treat unmet medical needs. The company's lead product is Accrufer/Feraccru, a non-salt based oral therapy for the treatment of iron deficiency with or without anemia in adults. It also develops PT20, a novel iron-based phosphate binder that has completed its Phase II pivotal study for the treatment of hyperphosphatemia in patients with chronic kidney disease.
- CEO
- Anders Lundstrom
- IPO
- 2016
- Employees
- 63
- HQ
- Gateshead, GB
Price Chart
Valuation
- Market Cap
- $66.88M
- P/E
- -5.76
- P/S
- 2.00
- P/B
- -5.92
- EV/EBITDA
- -13.35
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 43.89%
- Op Margin
- -19.55%
- Net Margin
- -34.53%
- ROE
- 103.62%
- ROIC
- -58.30%
Growth & Income
- Revenue
- $50.74M · 101.49%
- Net Income
- $-18,025,406 · 15.26%
- EPS
- $-0.02 · 12.77%
- Op Income
- $-10,297,607
- FCF YoY
- -25.57%
Performance & Tape
- 52W High
- $12.50
- 52W Low
- $2.25
- 50D MA
- $8.17
- 200D MA
- $8.69
- Beta
- 1.88
- Avg Volume
- 2.44M
Get TickerSpark's AI analysis on STX.L
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Our STX.L Coverage
We haven't published any research on STX.L yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate STX.L Report →